Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramucirumab - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Ramucirumab - Eli Lilly and Company

Alternative Names: Anti-flk-1 monoclonal antibody - ImClone; Anti-KDR monoclonal antibody - ImClone; Anti-VEGFR 2 monoclonal antibody - ImClone; Cyramza; IMC-1121; IMC-1121-B; IMC-1C11 - ImClone; LY-3009806; Ramcilumab; ramsilmab; Ramsilomab; Ramsylmab; Ramsylumab; Sairamza; Silamza

Latest Information Update: 07 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dyax
  • Developer AstraZeneca; Basilea Pharmaceutica; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer
  • Phase III Oesophageal cancer; Urogenital cancer
  • Phase II Biliary cancer; Carcinoid tumour; Solid tumours; Synovial sarcoma
  • Phase I/II Adenocarcinoma; Head and neck cancer; Pancreatic cancer; Soft tissue sarcoma
  • No development reported Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 31 Jul 2024 Phase-I/II clinical trials in Adenocarcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan (IV) (NCT06445972)
  • 30 Jul 2024 Eli Lilly completed the phase II RAMTAS trial in Colorectal cancer (Combination therapy, Metastatic disease, Late-stage disease, Inoperable/Unresctable, Second-line therapy or greater) in Germany (IV) (NCT03520946)
  • 06 Jun 2024 Merck Sharp & Dohme plans a phase I/II MK-3475-06D/Keymaker-U06 trial for Adenocarcinoma (Combination therapy, second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in July 2024 (IV, Infusion) (NCT06445972)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top